RNA Therapeutics are redefining what is possible in drug discovery. They offer opportunities for an improved side effect profile and efficacy against previously intractable targets.
RNA Therapeutics aim to treat diseases by targeting gene expression or producing therapeutic proteins. These RNA-based therapies showcase a powerful modality, acting where more conventional small molecules and biologics often fall short.
However, their true impact is still limited by complex delivery challenges, including a narrow biodistribution and restricted cell targeting.
The use of next-generation delivery systems, such as lipid nanoparticles and tissue-specific formulations or conjugates, could address these limitations and expand the range of treatable diseases, enabling more precise control over when and where the therapy acts.
We are working in partnership with industry and academia to strengthen the UK pipeline of advanced therapeutics. This is achieved through collaboration and the development of new partnerships in the field of RNA therapeutics and as part of the Intracellular Drug Delivery Centre (IDDC), an Innovate UK-funded programme, focused on the manufacturing, characterisation and development of nanoparticle formulations.
We recognise the exciting opportunity to redefine what is possible in drug discovery, using RNA therapeutics. IDDC is supporting innovators across the community to access nanoparticle delivery agents and to evaluate the biophysical properties of nanomedicines, which lead to a better understanding of how to achieve a Structure-Activity Relationship (SAR), an improved biodistribution and better targeting properties.
Our work in collaboration with CPI on IDDC is already making impact:
As a life sciences service, we strategically align scientific expertise, industry, charities, and patients to address global challenges for specific diseases or technologies.
We collaboratively develop national programmes, focused on delivering impact where support is needed to improve patients’ lives.
A partnership funded by Innovate UK, the IDDC brings together two UK Catapults (MDC and CPI) and three leading universities (imperial college london, University of Strathclyde and University of Liverpool) to develop novel drug delivery technologies and support promising RNA vaccines and therapeutics.
Visit websiteWant to collaborate or learn more about our work in RNA therapeutics? Or are you looking to develop or de-risk your RNA therapeutics?
Fill in the form today and speak to us to learn more.
